(86 days)
Mepitel is intended for the management of wounds in the granulation phase, especially painful wounds and wounds with newly formed delicate tissue such as pressure ulcers, venous and arterial leg ulcers, diabetic ulcers, surgical incisions, second degree burns, skin abrasions, lacerations, partial and full thickness grafts, and skin tears.
Mepitel is a sterile wound dressing which consists of three components: a medical grade silicone gel, a polyamide tricot net, and a low density polyethylene protective release liner. The dressing is delivered sterile in single packs and is available in the following sizes: 2" x 3" (5 cm x 7.5 cm); 3" x 4" (7.5 cm x 10 cm); 4" x 8" (10 cm x 18 cm); and 9" x 12" (20 cm x 30 cm).
This document is a 510(k) summary for a medical device called Mepitel® Non Adherent Silicone Dressing. It does not contain information about acceptance criteria or a study proving that the device meets such criteria.
The document primarily focuses on establishing substantial equivalence to a predicate device, which is the regulatory pathway for this type of device. Substantial equivalence means the new device is as safe and effective as a legally marketed device. This process typically involves comparisons of material composition, intended use, and technological characteristics, and often includes biocompatibility testing. It generally does not involve detailed performance studies with acceptance criteria in the way described in your request for AI/diagnostic devices.
Here's why the requested information cannot be found in the provided text:
- Type of Device: This is a wound dressing, not an AI, diagnostic, or image-generating device. Its evaluation focuses on biocompatibility, physical properties, and a comparison to an existing similar product, rather than performance metrics like sensitivity, specificity, or reader improvement.
- Regulatory Pathway: The 510(k) pathway for wound dressings relies heavily on demonstrating substantial equivalence to a predicate device. This means showing that the new device has the same intended use, similar technological characteristics, and is as safe and effective as one already on the market. It does not typically require performance studies with detailed acceptance criteria and ground truth establishment as would be required for a novel diagnostic or AI device.
Therefore, none of the specific points you asked for (acceptance criteria and reported performance, sample sizes, expert qualifications, adjudication methods, MRMC studies, standalone performance, type of ground truth, training set information) are present in this 510(k) summary. The study mentioned ("Mepitel have been found to be non-toxic and non-irritating when tested in accordance with the ISO 10993 Part I") is a biocompatibility test, not a performance study as requested.
N/A